A new, rich information source to aid pharmaceutical development
As paediatric medicines come under increasing focus from European regulatory authorities the need to understand this sensitive market is more important than ever.
Over two-thirds of paediatric patients receive prescriptions for unlicensed and off-label drugs and as few as 20% of new medicines are formally tested in children. New legislation both in Europe and the USA is aimed at increasing the information available on the use of medicines in children(1).
Italy is one of the few countries with a specific primary care system devoted to children up to 14 years of age. This is supported by a network of family paediatricians, many of whom contribute to the ongoing collection of paediatric-specific longitudinal information.
IMS already provides the gold standard of longitudinal patient level databases in the primary care setting. Now, through a unique collaboration with the leaders of the Italian paediatric network, we are delighted to make this rich information available to help the ongoing analysis of paediatric prescribing in both primary and secondary care.
Comphrensive Coverage
NEW paediatric insights from IMS Health enable sophisticated retrospective and prospective studies to be conducted, enhanced by the availability of rich free-text for in-depth analysis. Coverage includes:
- 5 years back-data
- Paediatric patients aged 0-14 years
- 118 participating paediatricians
- Over 160,000 longitudinal paediatric records
- Diagnosis, demographics, symptoms, reason for visits, prescribing information, dosage, lab tests, auxology, hospitalisations (including length of stay), vaccinations, and specialist referrals (including specialist notes)
Addressing key business
Paediatric insights can support your most pressing challenges in the development of medications for children in such areas as:
- Brand differentiation claims support
- Pediatric development requirements
- Risk minimisation plans
- Pharmacovigilance
- Pediatric extension lines
- Pricing and reimbursement
- Health economics support
- Prospective clinical studies
